HK1152474A1 - 用於預防和治療膿毒症的方法和組合物 - Google Patents

用於預防和治療膿毒症的方法和組合物

Info

Publication number
HK1152474A1
HK1152474A1 HK11106525.8A HK11106525A HK1152474A1 HK 1152474 A1 HK1152474 A1 HK 1152474A1 HK 11106525 A HK11106525 A HK 11106525A HK 1152474 A1 HK1152474 A1 HK 1152474A1
Authority
HK
Hong Kong
Prior art keywords
sepsis
prevention
compositions
treatment
methods
Prior art date
Application number
HK11106525.8A
Other languages
English (en)
Inventor
Sek Chung Fung
Tom Eirik Mollnes
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1152474A1 publication Critical patent/HK1152474A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11106525.8A 2003-05-15 2011-06-23 用於預防和治療膿毒症的方法和組合物 HK1152474A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47068103P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
HK1152474A1 true HK1152474A1 (zh) 2012-03-02

Family

ID=33476736

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106525.8A HK1152474A1 (zh) 2003-05-15 2011-06-23 用於預防和治療膿毒症的方法和組合物

Country Status (11)

Country Link
US (1) US8329169B2 (zh)
EP (2) EP2266606B1 (zh)
JP (2) JP4768620B2 (zh)
CN (2) CN102258784A (zh)
AU (2) AU2004241069B2 (zh)
CA (1) CA2524534C (zh)
DK (1) DK1628530T3 (zh)
ES (2) ES2387275T3 (zh)
HK (1) HK1152474A1 (zh)
MX (1) MXPA05011886A (zh)
WO (1) WO2004103294A2 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001332A2 (en) * 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
US8420783B2 (en) 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
CN101932337A (zh) * 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
AU2010264520A1 (en) 2009-06-23 2012-01-19 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
EP2309001A1 (de) * 2009-09-23 2011-04-13 SIRS-Lab GmbH Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen
WO2011106635A1 (en) * 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2545075B1 (en) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
SG185383A1 (en) * 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
WO2012145392A2 (en) * 2011-04-18 2012-10-26 Curators Of The University Of Missouri Saccharide conjugates
JP5793188B2 (ja) 2011-05-13 2015-10-14 国立大学法人 東京大学 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６
CN103649756B (zh) * 2011-05-19 2016-07-06 持田制药株式会社 使用血液样本的呼吸道传染病的诊断
AU2012279288B2 (en) 2011-07-01 2017-07-20 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
CN102363781A (zh) * 2011-10-19 2012-02-29 海南大学 一种有效抑制小鼠mCD14基因表达的小干扰核糖核酸分子
CN102533758B (zh) * 2011-10-19 2014-04-02 海南大学 一种抑制水牛膜分化抗原14 基因表达的小核糖核酸分子
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
EP2914291B1 (en) 2012-11-02 2022-02-23 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
WO2014186599A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
AU2014287221C1 (en) 2013-07-09 2020-03-05 Annexon, Inc. Anti-complement factor C1q antibodies and uses thereof
EA034870B1 (ru) * 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
US20150104445A1 (en) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
EP3071217A2 (en) * 2013-11-18 2016-09-28 Westfälische Wilhelms-Universität Münster Methods, peptides and antibodies for preventing, treating and diagnosing an inflammatory condition
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
NZ727420A (en) 2014-06-12 2018-06-29 Ra Pharmaceuticals Inc Modulation of complement activity
AU2015343029B2 (en) 2014-11-05 2021-07-29 Annexon, Inc. Humanized anti-complement factor C1q antibodies and uses thereof
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
PT3250230T (pt) 2015-01-28 2021-12-07 Ra Pharmaceuticals Inc Moduladores da atividade do complemento
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
WO2017075189A1 (en) 2015-10-27 2017-05-04 University Of Massachusetts Factor h-fc immunotherapy
JP6976943B2 (ja) 2015-11-24 2021-12-08 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用
EP3389692B1 (en) 2015-12-16 2020-03-04 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2017134043A1 (en) * 2016-02-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for neutralising the cytotoxic activity of extracellular histone proteins in subjects suffering from sepsis
US11123399B2 (en) 2016-12-07 2021-09-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2019112984A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
EP3947352A1 (en) 2019-03-29 2022-02-09 RA Pharmaceuticals, Inc. Complement modulators and related methods
MX2021013010A (es) 2019-04-24 2022-01-18 Ra Pharmaceuticals Inc Composiciones y metodos para modular la actividad del complemento.

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3785967T2 (de) * 1986-04-28 1993-12-02 Cetus Corp Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung.
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JP2744130B2 (ja) * 1989-08-01 1998-04-28 スクリップス クリニック アンド リサーチ ファウンデーション 敗血症治療用組成物
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
DE4029227A1 (de) 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
AU2694592A (en) 1991-09-30 1993-05-03 Walser, Mackenzie Methods for treatment of free-radical-mediated tissue injury
CA2133758A1 (en) * 1992-04-06 1993-10-14 Sanna M. Goyert A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
AU685433B2 (en) 1993-02-12 1998-01-22 Regents Of The University Of Minnesota Pulmonary administration of sCR1 and other complement inhibitory proteins
ATE335072T1 (de) 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
SK283096B6 (sk) * 1994-07-05 2003-02-04 Steeno Research Group A/S Imunomodulátory
WO1996008272A1 (en) * 1994-09-16 1996-03-21 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
EP0800534A2 (en) * 1994-12-23 1997-10-15 Laboratoires Om S.A. Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6042821A (en) 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
EP0901379B1 (en) * 1996-05-22 2000-09-06 University Of Alberta Type-2 chemokine binding proteins and methods of use therefor
WO1998017312A1 (fr) 1996-10-22 1998-04-30 Chugai Seiyaku Kabushiki Kaisha Remede contre les troubles septiques et comprenant un anticorps anti-il-8 en qualite d'ingredient actif
US6172220B1 (en) 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
EP0911400A1 (en) 1997-03-07 1999-04-28 Mochida Pharmaceutical Co., Ltd. Antisense compounds to cd14
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
PL345208A1 (en) 1998-05-27 2001-12-03 Gemma Biotechnology Ltd The induction of antiobiotic proteins and peptides by lait/scd14-protein
EP1115875A1 (en) * 1998-09-24 2001-07-18 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
CN1324244A (zh) * 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
US20030114377A1 (en) * 1998-11-18 2003-06-19 Kirkland Theo N. Inhibition therapy for septic shock with mutant CD14
DE19913707A1 (de) 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
JP4489976B2 (ja) * 1999-04-09 2010-06-23 ビーエーエスエフ ソシエタス・ヨーロピア 補体プロテアーゼの低分子インヒビター
ATE308985T1 (de) * 1999-05-18 2005-11-15 Teijin Ltd Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
AU2001234925A1 (en) * 2000-02-08 2001-08-20 The University Of Virginia Patent Foundation Methods for the prevention and treatment of infections using anti-C3b(i) antibodies
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US20040092712A1 (en) * 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor
EP1275713A4 (en) * 2000-03-31 2004-06-30 Mochida Pharm Co Ltd BINDING INHIBITOR BETWEEN THE TOLL-TYPE RECEPTOR AND CD14
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
JPWO2002042333A1 (ja) * 2000-11-22 2004-03-25 持田製薬株式会社 Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体
AU2002256971B2 (en) 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20030077576A1 (en) * 2001-03-20 2003-04-24 Joann Trial Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
DK1425028T3 (da) 2001-05-16 2010-03-01 Yeda Res & Dev Anvendelse af IL-18 inhibitorer til behandling eller forebyggelse af sepsis
ES2283594T5 (es) * 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury

Also Published As

Publication number Publication date
AU2004241069B2 (en) 2010-09-09
MXPA05011886A (es) 2006-02-17
CA2524534A1 (en) 2004-12-02
ES2387275T3 (es) 2012-09-19
CA2524534C (en) 2012-12-11
ES2522525T3 (es) 2014-11-14
EP1628530B1 (en) 2012-06-06
AU2004241069A1 (en) 2004-12-02
CN102258784A (zh) 2011-11-30
JP2006528981A (ja) 2006-12-28
US8329169B2 (en) 2012-12-11
AU2010249190A1 (en) 2011-01-06
CN1787741B (zh) 2011-08-17
CN1787741A (zh) 2006-06-14
EP2266606A1 (en) 2010-12-29
AU2010249190B2 (en) 2013-02-28
EP1628530A2 (en) 2006-03-01
WO2004103294A2 (en) 2004-12-02
EP2266606B1 (en) 2014-09-10
EP1628530A4 (en) 2007-08-29
US20070274989A1 (en) 2007-11-29
WO2004103294A3 (en) 2005-05-26
JP2011105747A (ja) 2011-06-02
EP1628530B8 (en) 2012-08-01
JP4768620B2 (ja) 2011-09-07
DK1628530T3 (da) 2012-07-23

Similar Documents

Publication Publication Date Title
HK1152474A1 (zh) 用於預防和治療膿毒症的方法和組合物
PT1644021E (pt) Métodos e composições para o tratamento de distúrbios gastrointestinais
ZA200704677B (en) Compositions and methods for the treatment of autism
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-S
EP1692085A4 (en) INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA
EP1711197A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
IL174627A0 (en) Compositions and methods for treatment of burns
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
AU2003256805A8 (en) Compounds compositions and methods
EP1720563A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1651255A4 (en) TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS
AU2003297573A8 (en) Compositions and methods for treating transplants
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
SI1812797T1 (sl) Pripravki in metode zdravljenja ter preprečevanja hiperprolifetarivnih bolezni
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB0324523D0 (en) Compositions and methods of treatment
EP1755581A4 (en) METHODS AND COMPOSITIONS FOR TREATING MYOCARDIAL CONDITIONS
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB0313630D0 (en) Compositions for the enhanced treatment of depression

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200518